Albemarle Corporation (ALB)

Albemarle's stock is trading near the bottom of its 52-week range after a steep slide over the past six months, even as its operating results have improved. The shares closed at $94.93, down 4.23% in the last session, and sit 5.75% above the 52-week low of $89.77. The stock is still well below its 50-day and 200-day moving averages ($105.98 and $147.03), so the trend remains down. The question for investors is whether earnings strength and analyst support can outweigh a price that has not yet recovered its footing.

Albemarle's results have been running ahead of expectations. Adjusted EPS of $2.58 in the November 4, 2026 report beat the $2.53 estimate by 1.98%, and the stock rose 3.58% in the following session. The August 5, 2026 report was stronger, with $3.75 against $3.24, a 15.74% beat, and the shares rose 5.54% after it. The May 6, 2026 report beat by 125.19%, though that was against a low estimate of $1.31. Over the eight reports on record, six beat estimates. Yet the share price still fell 26.62% over three months and 53.81% over six months. The market appears to be discounting the earnings outlook rather than the current quarter's results.

On trailing earnings, the stock trades at 22.87 times, a discount to the sector median P/E of 30.2. The price-to-sales ratio of 1.82 is 56.7% below the sector median of 4.2. Trailing GAAP EPS is $4.15, and the company's market capitalisation is $11.2B. The discount reflects the weak profitability: return on equity is 7.05% against a sector median of 17.9%, and the net profit margin is 8.4%. The balance sheet is conservative, with debt-to-equity at 0.18, and the company is rated 3 of 5 for health.

Revenue grew 18.80% in the latest quarter year on year, slightly below the sector median of 19.0%. Analysts expect revenue to grow 17.6% this fiscal year to about $6.0B, but they forecast earnings per share to shrink 17.6% next year. That split between top-line growth and falling earnings is central to the debate. The stock's beta of 1.36 means it has moved more than the broader market, and its typical daily move is 2.34%.

Over the last 18 months, insiders sold $7.4M of stock across six sales and bought $18K in one open-market purchase. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less signal than open-market buying. The small purchase is the only insider transaction that was made in the market rather than tied to compensation.

The base case for the coming months is that ALB stays volatile and range-bound while it works back toward its moving averages. Its last two reports beat estimates, and the shares rose the session after each, which suggests the earnings trend is intact. Analysts remain constructive: 14 of 23 rate the stock Buy or Strong Buy, none rate it Sell, and the median 12-month target is $135.00, well above the current price. Two conditions would support that view: a reclaim of the 20-day EMA at $96.98 and then the 50-day SMA at $105.98, with revenue growth holding near its recent pace. A close below the 52-week low of $89.77 would weaken the case and bring the lower analyst targets, such as $83.28, into position. Analysts expect earnings per share to shrink next year, from $10.56 this year to $8.70 in 2027, so that forecast is a key risk to the bullish targets.

Support sits at the 52-week low of $89.77, the nearest level below the price and the line where a fall would meet first. A break there would open the door to lower levels further down. Resistance comes first at the 20-day exponential moving average of $96.98, which a rise would meet first, followed by the 50-day simple moving average of $105.98, which has been the level the stock has traded below since its recent decline.